Nobivac^® DHPPi Questions and Answers

For active immunisation of dogs:

• To prevent mortality and clinical signs caused by canine distemper virus infection.
• To reduce clinical signs of infectious hepatitis and viral excretion due to canine adenovirus type 1 infection.
• To prevent mortality, clinical signs and viral excretion following canine parvovirus infection.
• To reduce clinical signs and viral excretion caused by canine parainfluenza virus infection and to reduce clinical signs of respiratory disease and viral excretion following adenovirus type 2 infection.

Where earlier protection is required a first dose may be given to puppies from 6 weeks of age, but because maternally derived passive antibody can interfere with the response to vaccination a final dose at 10 weeks of age or older is generally recommended.

For an optimal response to the parainfluenza component, animals should be vaccinated twice, 2-4 weeks apart with the final vaccination at 10 weeks of age or older.

In the event that the initial primary course dose of Nobivac DHPPi is delayed to 10 weeks of age or older, a single dose of Nobivac Pi at 12 weeks of age or older should suffice to establish optimal immunity for this component.

Nobivac DHPPI requires storage in a refrigerator between 2 ^oC and 8 ^oC. Do not freeze. Protect from light. Care should be taken to avoid prolonged or repetitive exposure to high ambient temperatures following withdrawal from the refrigerator prior to use - in hot summer conditions vaccine potency can be severely reduced within a few hours.

A single injection should establish active immunity to canine distemper, infectious canine hepatitis and disease caused by canine parvovirus infection in dogs of 10 weeks of age or older. 

In the event that the initial primary course dose of Nobivac DHPPi is delayed to 10 weeks of age or older, a single dose of Nobivac Pi at 12 weeks of age or older should suffice to establish immunity for this component.

At least three years for the canine distemper virus, canine adenovirus and canine parvovirus vaccine components.

The duration of immunity for the canine parainfluenza virus component has not been demonstrated, but an anamnestic response is produced in dogs given a revaccination one year after basic vaccination. Annual revaccination with the canine parainfluenza virus vaccine component is recommended.

The onset of immunity is 1 week for canine distemper virus, canine adenovirus and canine parvovirus vaccine components and 4 weeks for canine parainfluenza virus vaccine component.

There are no breed-specific contraindications for Nobivac DHPPi.

Nobivac DHPPi can be used in pregnant bitches which have previously been vaccinated with the CDV (strain Onderstepoort), CAV2 (strain Manhattan LPV3), CPV (strain 154) and CPi (strain Cornell) antigens included in the Nobivac vaccine series.

We do not hold specific data regarding use during lactation and therefore use must be on a risk vs benefit decision during this delicate time for the bitch.

Safety and efficacy data (viral excretion) are available which demonstrate that this vaccine can be mixed and administered with the inactivated vaccines of the Nobivac series against canine leptospirosis caused by all or some of the following serovars: L. interrogans serogroup Canicola serovar Canicola, L. interrogans serogroup Icterohaemorrhagiae serovar Copenhageni, L. interrogans serogroup Australis serovar Bratislava, and L. kirschneri serogroup Grippotyphosa serovar Bananal/Liangguang.

Safety data and efficacy data for the canine distemper virus, canine adenovirus and canine parvovirus components of this vaccine are available which demonstrate that this vaccine can be administered at the same time but not mixed with the inactivated vaccine of the Nobivac series against Bordetella bronchiseptica.

When this vaccine is administered in association with the inactivated vaccine of the Nobivac series against Bordetella bronchiseptica, the demonstrated antibody response data for the live canine parainfluenza component of this vaccine are the same as when this vaccine is administered alone.

The product information of the relevant Nobivac vaccines should be consulted before administration of the mixed product. When mixed with Nobivac leptospirosis vaccines at annual revaccination, it has been established that there is no interference with the anamnestic response induced by the injectable canine parainfluenza virus component.

After mixed administration of an overdose of Nobivac DHPPi and an overdose of the leptospirosis vaccines of the Nobivac series, transient local reactions such as diffuse to firm swellings from 1 to 5 cm in diameter may be observed, usually these will persist no longer than 5 weeks, however some may take a little longer to completely disappear.

When Nobivac DHPPi is used with any of the other Nobivac vaccines referred to above, the minimum vaccination age for each vaccine must be taken into account such that at the time of vaccination, the dogs are at or older than the oldest minimum vaccination age for the individual vaccines.

Safety and efficacy data are available which demonstrate that this vaccine can also be administered on the same day with Nobivac^® Solvent or Nobivac^® Rabies. These can be used to reconstitute the freeze-dried Nobivac DHPPi.

In the situation that concurrent vaccination with Nobivac DHPPi, Nobivac^® Lepto 2 and Nobivac Rabies is desired it is advisable to mix Nobivac DHPPi either with Nobivac Lepto 2 or Nobivac Rabies and to administer as 2 separate injections.